Merck quarterly profit tops expectations on COVID pill surprise
By Michael Erman (Reuters) -Merck & Co on Thursday reported
merck
Germany’s Merck flags steeper drop in earnings
By Ludwig Burger FRANKFURT (Reuters) -Germany’s Merck KGaA on Thursday
Merck to take $10.3 billion R&D charge for Prometheus deal this year
(Reuters) – Merck & Co expects a research-and-development charge of
Pfizer, Merck trim prices in China for Paxlovid, molnupiravir – reports
SHANGHAI (Reuters) – Pfizer and Merck have slightly lowered the
Mersana signs deal with Merck KGaA for cancer therapy development
(Reuters) – Mersana Therapeutics Inc said on Thursday it had
Merck KGaA in push to become twice as productive in drug development
FRANKFURT (Reuters) – Germany’s Merck KGaA on Monday said it
Merck avoided billions in U.S. tax by offshoring Keytruda profits – senator
By Michael Erman (Reuters) – Drugmaker Merck & Co avoided
Orion raises outlook after Merck deal on developing prostate cancer drug
(Reuters) -Finnish drug maker Orion on Wednesday raised its full
Merck considering purchase of cancer drug maker Seagen – WSJ
(Reuters) – Drugmaker Merck & Co is considering buying cancer-focused
Merck Japan says to accelerate imports of COVID-19 treatment
TOKYO – The Japanese unit of Merck & Co Inc
Merck Says COVID-19 Pill Less Effective Than Initially Suggested
Merck announced Friday that updated data on its experimental COVID-19